COVID Vaccine Authorization Changes Without Advisory Committee Becoming More Common

Vaccine booster
The change in the time between the Pfizer/BioNTech primary series and booster may create more confusion for recipients and providers. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet